

1 **A novel method for measuring phenotypic colistin resistance in *Escherichia coli***
2 **populations from chicken flocks**

3 Nhung Thi Nguyen^a, Nguyen Thi Phuong Yen^a, Nguyen Van Ky Thien^a, Nguyen Van Cuong^a,
4 Bach Tuan Kiet^b, James Campbell^{a,c}, Guy Thwaites^{a,c}, Stephen Baker^d, Ronald B. Geskus^{a,c}, Juan
5 Carrique-Mas^{a,c}

6 ^aOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

7 ^bSub-Department of Animal Health and Production, Dong Thap province, Vietnam

8 ^cCentre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine,
9 Oxford University, Oxford, United Kingdom

10 ^dCambridge Institute of Therapeutic Immunology & Infectious Disease, University of
11 Cambridge, Cambridge, United Kingdom

12 **Running title:** Method for measuring colistin resistance in chicken

13 **KEYWORDS**

14 Poultry, colistin resistance, broth microdilution, colistin use.

15 **Corresponding author**

16 Nguyen Thi Nhung

17 Senior Microbiologist

18 ViParc Project Laboratory co-ordinator

19 Oxford University Clinical Research Unit

20 764 Vo Van Kiet, Ward 1, District 5

21 Ho Chi Minh City (Vietnam)

22 E-mail: nhungnt@oucru.org

23 **ABSTRACT**

24 Colistin is extensively used in animal production in many low- and middle-income countries.
25 There is a need to develop methodologies to benchmark and monitor changes in resistance in
26 commensal bacterial populations in farms. We aimed to evaluate the performance of a broth
27 microdilution method based on culturing a pooled *Escherichia coli* suspension (30-50
28 organisms) from each sample. In order to confirm the biological basis and sensitivity of the
29 method, we prepared 16 standard suspensions containing variable ratios of colistin-susceptible
30 and *mcr-1* encoded colistin-resistant *E. coli* which were grown in 2mg/L colistin. The optical
31 density (OD_{600nm}) readings over time were used to generate a growth curve, and were adjusted to
32 the values obtained in the absence of colistin. The median limit of detection of the method was 1
33 colistin-resistant in 10⁴ susceptible colonies [1st - 3rd quartile, 1:10² – 1:10⁵]. We applied this
34 method to 108 pooled faecal samples from 36 chicken flocks in the Mekong Delta (Vietnam)
35 over the production cycle. The correlation between this method and the prevalence of colistin
36 resistance in individual colonies harvested from field samples, determined by the Minimum
37 Inhibitory Concentration (MIC), was established. The overall prevalence of colistin resistance at
38 sample and isolate level was 38.9% and 19.4%, respectively. Increased colistin resistance was
39 associated with recent (2 weeks) use of colistin and other, non-colistin antimicrobials (OR=3.67
40 and OR=1.84, respectively). Our method is a sensitive and affordable approach to monitor
41 changes in colistin resistance in pooled *E. coli* populations from faecal samples over time.

42 **IMPORTANCE**

43 Colistin (polymyxin E) is an antimicrobial with poor solubility properties, and therefore broth
44 microdilution is the only appropriate method for testing colistin resistance. However, estimating
45 colistin resistance in commensal mixed *Escherichia coli* populations is laborious since it requires
46 individual colony isolation, identification and susceptibility testing. We developed a growth-
47 based microdilution method suitable for pooled faecal samples. We validated the method by
48 comparing it with results from individual MIC testing of 909 *E. coli* isolates. We used the
49 method to investigate phenotypic colistin resistance in 108 pooled faecal samples from 36
50 healthy chicken flocks, each sampled three times over the production cycle. A higher level of
51 resistance was seen in flocks recently supplemented with colistin in drinking water, although the
52 observed generated resistance was short-lived. Our method is affordable, and may potentially be
53 integrated into surveillance systems aiming at estimating the prevalence of resistance at colony
54 level in flocks/herds. Furthermore, it may also be adapted to other complex biological systems,
55 such as farms and abattoirs.

56 INTRODUCTION

57 Colistin (polymyxin E) is a last-resort drug used for the treatment of severe multi-drug resistant
58 (MDR) infections in many countries, and currently is classified by the World Health
59 Organization (WHO) as a ‘highest priority, critically important’ antimicrobial (1). The
60 emergence of *mcr-1* plasmid-encoded colistin resistance among Gram-negative bacteria is
61 considered a serious threat to global health (2). It has been hypothesized that colistin use in
62 animal production is a major contributing factor to the emergence of colistin resistance
63 worldwide (3). Colistin is still used in poultry and pig farming in many countries (4). In terms of
64 frequency, colistin is the most commonly used antimicrobial in chicken production in the
65 Mekong Delta region of Vietnam (5, 6). Studies in the same region have shown that resistance
66 against colistin in commensal *Escherichia coli* from chicken flocks is often encoded by the *mcr-*
67 1 gene (7, 8). At sample level, the prevalence of *mcr-1* in chicken faecal samples in the Mekong
68 Delta was 59.4%. The prevalence of this gene has also be found to be higher among in-contact
69 humans (chicken farmers) than in urban individuals (7).

70 *E. coli* is an ubiquitous commensal enteric organism globally used to monitor phenotypic
71 antimicrobial resistance (AMR) in national surveillance programmes, both in humans and in
72 animals (9, 10). Given the diversity of this organism within the enteric microbiome, the
73 characterisation of phenotypic resistance in a mixed population of commensal *E. coli* requires
74 selecting a representative and sufficiently large number of strains. This is often achieved by
75 performing differential colony counts on agar media with and without antimicrobials (11).
76 However, agar-based methods are not appropriate for colistin given the antimicrobials’ poor
77 solubility (12). Determination of the minimal inhibitory concentration (MIC) by broth
78 microdilution is regarded as the gold standard for testing of colistin resistance of

79 Enterobacteriaceae (ISO 20776-1) both by the Clinical and Laboratory Standards Institute
80 (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (12,
81 13). Establishing accurately the prevalence of resistance at colony level requires the investigation
82 of a sufficiently large, representative number of isolates from each sample, which is extremely
83 laborious and costly (8, 11, 14). Therefore, there is a need for developing cost-effective
84 methodologies for evaluating resistance against colistin in mixed *E. coli* populations from animal
85 faecal samples. Here, we designed and evaluated a broth microdilution-based method to quantify
86 colistin resistance in *E. coli* populations from pooled chicken faecal samples. We then related the
87 observed results to data on antimicrobial use (AMU) from the same flocks.

88 RESULTS

89 Growth of standard suspensions

90 The AUC_{adj} values generated from all susceptible-resistant combinations are presented in Fig.1.
91 In all cases, AUC_{adj} values increased with increasing ratio of resistant to susceptible organisms.
92 Growth was detected at a ratio of 1 resistant to 10⁵, 10⁴, 10³, 10² and 10¹ susceptible strains for
93 43.7%, 12.5%, 18.5% and 12.5% and 12.5% combinations, respectively. There was no difference
94 in average AUC_{adj} between resistant strains with low (R1 and R2, MIC= 4mg/L) and moderate
95 (R3 and R4, MIC= 8mg/L) levels of resistance (both AUC_{adj}= 0.39). There were significant
96 difference between average AUC_{adj} values using different susceptible strains, with values
97 ranging from 0.09 to 0.62 (Kruskal Wallis test, p= 0.002). In combinations with resistant strains,
98 S2 yielded the lowest average AUC_{adj} (median 0.09 [1st - 3rd quartile, 0.07-0.29]) as well as the
99 lowest limit of detection (average S:R ratio of 10²:1). S4 gave the highest median AUC_{adj} (0.62
100 [1st - 3rd quartile, 0.48-0.69]) as well as the highest limit of detection (average S:R ratio of 10⁵:1).

101

102 **Study flocks and their AMU**

103 A total of 36 flocks (108 samples) were investigated in this study. The median flock size was 231
104 [1st - 3rd quartile, 189-401] chickens. Flocks were raised over a median of 19 [1st - 3rd quartile,
105 17-20] weeks. Colistin had been administered to 22/36 (61.1%) flocks. Among flocks given
106 colistin, the average number of Animal Daily Doses (ADD) per 1,000 chicken-days of this
107 antimicrobial administered over the production cycle was 149.5 Standard deviation [SD] ± 261.6 .
108 Colistin was used more during the early flock cycle period (281.7 SD ± 321.2 ADDs per 1,000
109 chicken-days) compared with the second period (17.4 SD ± 18.1 ADDs per 1,000 chicken-days)
110 (Wilcoxon paired test, $p < 0.001$) (Table 1). This antimicrobial was administered over a median
111 of 4 [1st - 3rd quartile, 2-6] weeks. The data of colistin use among study flocks is displayed in Fig.
112 S2.

113 In addition to colistin, a total of 28 non-colistin antimicrobials (belonging to 12 classes) were
114 administered to study flocks.. In decreasing order, oxytetracycline, tylosin, neomycin, ampicillin,
115 streptomycin and doxycycline were the antimicrobials most used. The average number ADDs
116 per 1,000 chicken-days of other antimicrobials among flocks using colistin was higher than
117 flocks did not use colistin (350.9 SD ± 383.8 vs. 187.2 SD ± 366.2 , Wilcoxon test, $p = 0.004$).
118 Among both type of flocks, antimicrobials were administered more commonly during the first
119 period (average No. ADD per 1,000 chicken-days 629.3 SD ± 359.8 and 345.5 SD ± 471.5 ,
120 respectively) compared to the second period of chicken life (average No. ADDs per 1,000
121 chicken-days 72.5 SD ± 98.5 and 29.0 SD ± 48.6 , respectively) (Table 1).

122 **Prevalence of colistin resistance at colony level**

123 A total of 909 *E. coli* strains were isolated from 23 selected samples (~40 *E. coli* isolates/
124 sample) and were tested for their MIC against colistin. Among those, total of 129 strains (14.2%)

125 were resistant to colistin. Of resistant strains, 75.2% strains had a MIC of 4 mg/L, whereas
126 24.0% had a MIC of 8mg/L. Only 1 isolate (0.8%) displayed a MIC of 16mg/L (Fig. S1). The
127 beta-regression model that relates the AUC_{adj} to percentage of resistant bacteria in samples is
128 shown in Fig. 2. The trend over AUC_{adj} was highly significant ($p < 0.001$). The equation
129 $100/(1+e^{4.8-(7.04*AUC_{adj})})$ associated with this model was applied for estimating the prevalence of
130 colistin resistance at colony level among field samples.

131 **Changes of AUC_{adj} over production cycle and prevalence of colistin resistance**

132 Overall, there was no significant change colistin resistance (AUC_{adj}) over the production cycle
133 ($p = 0.569$, Fig. S3). Among flocks not exposed to colistin, the differences AUC_{adj} between
134 sampling points were small. However, among flocks using colistin, the AUC_{adj} values for mid-
135 production samples (0.54 [1st - 3rd quartile, 0.07-0.65]) were higher than those of day-olds (0.06
136 [1st - 3rd quartile, 0.04-0.52]) (Wilcoxon paired test, $p = 0.063$) and end of production samples
137 (0.07 [1st - 3rd quartile, 0.06-0.55]) (Wilcoxon paired test, $p = 0.046$). There was little to no
138 difference in AUC_{adj} values between day-old and end of production samples (Table 1).

139 The prevalence of colistin resistance at sample level was 38.9% (42/108 positive samples). The
140 prevalence of resistance level of day-old, mid-, and end of production samples was 36.1%,
141 50.0% and 30.5%, respectively (χ^2 test, $p = 0.219$). The overall average prevalence of resistance
142 at colony level was 19.4 SD \pm 26.3%. Among flocks using colistin, the highest level of resistance
143 corresponded to mid-production samples (27.0 SD \pm 26.4%), followed by day-old (15.7 SD \pm
144 24.7%) and end production (12.8 SD \pm 18.1%) (Kruskal Wallis test, $p = 0.070$). In contrast,
145 among non-using flocks, day-old samples showed higher prevalence of resistance (28.8 SD
146 \pm 36.0%) compared to mid (17.3 SD \pm 28.7%) and end production (16.2 SD \pm 24.8%) (Kruskal

147 Wallis test, $p= 0.453$). Summary results are presented in Table 1 and individual sample results
148 are given in Table S1.

149 **Risk factors for colistin resistance**

150 Table 2 shows results for univariable and multivariable analyses. In the multivariable model, use
151 of colistin during the two weeks prior to sampling (OR= 3.67; 95% [Confidence Interval] CI
152 0.68-19.7) and use of non-colistin antimicrobials (OR= 1.84; 95% CI 0.88-3.85) were associated
153 with colistin resistance at sample level.

154 **Estimation of test costs**

155 The reagent and media costs of broth microdilution and Etest for testing one sample based on the
156 investigation of 10 *E. coli* isolates were ~24.5 and ~63 US dollars (USD), respectively. The cost
157 for testing one sample by the growth-based method (based on 40 isolates) was ~6.5 USD. In
158 addition, broth microdilution involved a higher labour cost (average of ~1 person-day per
159 sample) compared with either the Etest or the growth-based method (~0.5 person-day) (Table
160 S2).

161 **DISCUSSION**

162 We present here an approach for the phenotypic investigation of colistin resistance in pooled *E.*
163 *coli* populations from poultry feces using a broth microdilution-based method. Colistin is widely
164 used in poultry and pig production worldwide (4, 15, 16). In the Mekong Delta of Vietnam,
165 colistin is typically administered to chicken flocks in drinking water during the brooding period
166 (1-4 weeks) with a prophylactic purpose (i.e. to prevent disease) (5). Colistin is also included in
167 some pig and poultry commercial feeds as a growth promoter (AGP) (17). However, from 2020
168 onwards, AGPs are longer be allowed in Vietnam (Law No. 32/2018/QH14), in line with
169 legislative restrictions in Thailand (2015) (18), China (2016) (19) and India (2019) (20).

170 In contrast with the study of human patients, where colistin susceptibility testing is required to
171 inform therapeutic choices (21) our method is aimed at estimating colistin resistance in mixed
172 commensal *E. coli* populations. Through evaluation of the growth curves of standard *E. coli*
173 suspensions from faecal samples, our method enables the detection of colistin resistance in a
174 dichotomous fashion (presence/absence), as well as providing a quantitative assessment of
175 colistin resistance at colony level (prevalence of resistant *E. coli*). The sensitivity of this
176 methodology is, however, limited by the number of colonies harvested per sample (30-50), and
177 may therefore miss colistin resistant strains in situations of very low prevalence. Indeed,
178 statistically, given a sample of 40 colonies, there is a 5% probability of not detecting colistin
179 resistance in any of them when the prevalence of resistant falls below 7.5%. Because of this, the
180 method is more suitable advised for situations of medium to high prevalence of colistin
181 resistance. The sensitivity could however be potentially increased by collecting several samples
182 or increasing the number of *E. coli* colonies used in each suspension. For example, detection of a
183 prevalence of 2% would require the investigation of 150 isolates (~4 samples, each with 30-50
184 colonies), detection of a prevalence of 1% would require 300 isolates (~8 samples); 0.1% a total
185 of 3,000 isolates (~75 samples).

186 Although there was a reasonable relationship between prevalence of resistance and AUC_{adj} , we
187 observed considerable variation in AUC_{adj} for similar prevalence values both in our laboratory
188 validation as well as on flock samples. This suggests variable growth capacity among resistant
189 strains, which may depend on their relative fitness. In the case of field suspensions containing a
190 diversity of susceptible and resistant strains, it is also likely that the relative composition of
191 strains may result in variable growth among the resistant strains due to the liberation of toxins
192 (i.e. colicins) in the culture media (22). This may also explain the variable limit of detection

193 confirmed in laboratory conditions with different susceptible strains. In general, given identical
194 prevalence of resistant strains, we observed higher AUC_{adj} values for individual susceptible-
195 resistant strain combinations, compared to the mixed of *E. coli* in field samples (Fig 2). It could
196 be probably explained by less competition exerted in mixes containing a single strain, compared
197 with heterogenous mixes containing ~40 different strains. Because of these reasons, prevalence
198 estimates derived from AUC_{adj} should be always interpreted with caution.

199 We believe that our testing approach is more efficient than isolating and investigating individual
200 colonies, at a relatively lower cost. However, it requires investment on a microplate reader
201 costing between 3,000 and 10,000 USD. The technique presented here could potentially be
202 adapted to the investigation of other types of phenotypic resistance in *E. coli* (i.e. tetracycline,
203 ampicillin, etc.) but it would necessarily require optimizing working concentrations.

204 At the colony level, we obtained a median prevalence of 19.4% colistin resistance in flocks.
205 These results are comparable with previous studies on chicken *E. coli* isolates in the area (12-
206 22%) (7, 8). Furthermore, the observed ~40% resistance at sample level is consistent with a
207 previous study on chickens in the Mekong Delta of Vietnam, where 5 *E. coli* colonies were
208 investigated from each of 18 faecal samples (8). In such study, a total of 8/18 (44%) samples
209 included at least one resistant strain (NT Nhung, personal communication). A PCR-based study
210 in this region reported that 59.4% chicken samples investigated tested positive for *mcr-1* gene
211 (7).

212 We demonstrated a short-term increase in phenotypic colistin resistance following administration
213 of colistin use as well as non-colistin antimicrobials. This contrasts with a study conducted on a
214 broiler flock in France, where administration of colistin failed to induce colistin resistance in
215 Enterobacteriaceae (including *E. coli*) (23). However, unlike in Vietnam, colistin use and

216 resistance (including *mcr-1*) is relatively rare in European livestock (10). Overall, we found
217 relatively high levels of colistin resistance (~40%), even in flocks that had not been given
218 colistin (33.3%). There was evidence of colistin resistance in mid-production samples from
219 flocks that had previously tested negative in day-old samples, and had not been administered
220 colistin (3 of 8 flocks) (data not shown). This suggests that colistin resistance may have been
221 generated or introduced to study flocks from other sources, such as contaminated water or feed,
222 or due to contamination with bacteria from other animal species present in these small-scale
223 farms.

224 Our findings of increased colistin resistance in flocks treated with antimicrobials other than
225 colistin are intriguing. In a previous study on Mekong Delta pig farms, colistin resistance in *E.*
226 *coli* strains was associated with use of non-colistin antimicrobials such as quinolones and
227 cephalosporins (8). The presence of genes conferring for resistance against several different
228 antimicrobial classes in *mcr*-harboring plasmids may explain these findings, and suggest that the
229 use of non-colistin drugs may also select for colistin resistance (24).

230 We observed a peak of colistin resistance in mid-production samples among flocks using
231 colistin, and generally levels of resistance decayed subsequently. This is likely to reflect the
232 higher frequency of colistin use during the brooding period. A longitudinal study on travelers
233 colonized by *mcr-I*-carrying bacteria showed that they were able to completely eliminate these
234 bacteria within one month after returning to their home country (25). The reasons for a reduction
235 in resistance over time are known and may be due to a combination of factors leading to plasmid
236 loss and/or fitness costs. However, studies in the laboratory have shown that the presence of
237 plasmid-mediated colistin resistance has been shown to confer no fitness costs to *E. coli* (26). It
238 is worthwhile noting that in our study chicken flocks were of local native breed, and they were

239 typically raised over a 4-5 month period, a period much longer than that required by industrial
240 broilers (typically 1.5 months). This suggests that birds slaughtered earlier may have a higher
241 prevalence of colistin resistance, and this potentially represents an additional risk to the
242 consumer.

243 In summary, we developed and validated an affordable method that may be effectively used to
244 quantify colistin resistance in commensal *E. coli* in chicken flocks. Our method may also be
245 adapted to benchmark and monitor changes over time in colistin resistance in faecal samples in
246 other complex biological systems such as abattoirs, slaughter-points and sewage, or even in
247 human individuals. Our results indicate a high background of colistin resistance even in flocks
248 not using this antimicrobial. The observed increases after colistin use were short-lived and
249 suggest that in small-scale farming systems reducing colistin resistance may require increasing
250 biosecurity as well as restocking colistin-negative day-old chicks.

251 **MATERIALS AND METHODS**

252 **Study design**

253 In order to investigate the biological basis and the limit of detection of the proposed method,
254 we used four previously characterized *mcr-1* colistin resistant *E. coli* strains, two displaying
255 moderate-level (MIC= 8mg/L) and two low-level (MIC= 4mg/L) colistin resistance, alongside
256 four colistin-susceptible strains. We prepared standard bacterial suspensions consisting of a
257 mix of each of the resistant and the susceptible strains at different ratios; these were incubated
258 in medium with and without 2mg/L of colistin. A growth curve from each suspension was
259 obtained by measuring the optical density (OD_{600nm}) during incubation. The area under the
260 curve (AUC_{adj}) of each colistin-containing standard suspension was adjusted by the AUC
261 values obtained from its equivalent colistin-free suspension. We investigated the relationship

262 between the prevalence of resistance at colony level and the observed AUC_{adj} from the
263 examination of 30-50 individual *E.coli* isolates from each of 23 samples and obtained a model
264 equation. We calculated AUC_{adj} values of suspensions consisting 30-50 *E. coli* colonies
265 harvested from each of 108 pooled faecal samples from 36 small-scale (single-age) chicken
266 flocks raised in Dong Thap province (Mekong Delta, Vietnam) (27). We inferred the
267 prevalence of resistant *E. coli* in flock samples investigated by extrapolation using the model
268 equation. The contribution of colistin use and other antimicrobials administered to flocks on
269 the observed phenotypic colistin resistance was investigated by building logistic regression
270 models with age as primary time variable.

271 **Culture of standard suspensions and calculation of AUC_{adj}**

272 Each of the chosen resistant *E. coli* strains (named R1 to R4, where R1 and R2 had MIC=
273 4mg/L; R3 and R4 had MIC= 8mg/L) and susceptible (all MIC \leq 1mg/L) strains (S1 to S4)
274 were incubated in cation adjusted Mueller Hinton II Broth II (MHB2, Sigma-Aldrich, USA) at
275 37°C, 200 rpm for 4h (log-phase) and these bacterial inoculum were adjusted to 10⁸ CFU/mL
276 (OD_{600nm}= 0.1), and then diluted down with MHB2 to 10⁶ CFU/mL. Each resistant strain was
277 mixed with a susceptible strain (total 16 combinations) at susceptible: resistant ratios ranging
278 from 0:1 (susceptible strain only) to 1:0 (resistant strain only). Intermediate ratios were 10:1,
279 10²:1, 10³:1, 10⁴:1, and 10⁵:1. A total of 100 μ L of each suspension was added into a well of
280 polystyrene microplate (Corning, USA), containing 100 μ L of colistin solution (final working
281 concentration was 2mg/L). In addition, respective colistin-free (control) suspensions were
282 prepared. Plates were incubated in a microplate reader (SPECTROStar, BMG Labtech,
283 Germany) at 37°C for 20h, and the turbidity (OD_{600nm}) readings were recorded every hour.. All
284 experiments were conducted in triplicate.

285 The areas under the curves (AUC) generated over the 20-hour observation period were
286 computed. The AUC value generated from each standard suspension ($AUC_{[i]}$) was related to the
287 AUC generated by its respective colistin-free control ($AUC_{adj} = AUC_{[i]} / AUC_{[0]}$).

288 **Flock sample and AMU data collection**

289 Fresh pooled faecal samples were collected from each flock at three time-points: (1) day-old
290 chicks, (2) mid-production (~2-3 months-old) and (3) end of production (~4-6 months-old).
291 Day-old faecal (i.e. meconium) samples were collected from the crates at the time when
292 chicks were delivered to the farms. For mid- and end-production sampling, sterile paper liners
293 were placed near drinkers and feeders in the chicken house/pen to collect deposited droppings.
294 After a minimum of 10 droppings had been deposited, liners were swabbed using sterile
295 gauzes. Each of collected gauze was placed in a universal jar and mixed vigorously with
296 50mL saline buffer. One ml of the resulting eluate was stored at -20°C with glycerol. Data on
297 AMU had been collected using purposefully designed diaries where farmers were asked to
298 note down all antimicrobials used. Farmers were instructed to keep all packages of
299 antimicrobials used on their flocks (5). Sample and data collection were conducted between
300 October 2016 and October 2018.

301 **Testing of pooled faecal samples**

302 Eluates from pooled faecal samples were plated onto ECC agar (CHROMagar, France) and
303 incubated at 37°C for 20h. A total of 30-50 *E. coli* (blue) colonies from each agar sample were
304 picked, pooled and incubated in CAMHB to log-phase. The resulting bacterial suspensions
305 were investigated as described above.

306

307 **Prevalence of colistin resistance at colony level**

308 We selected a number of positive samples with variable levels of AUC_{adj} . From each sample, 40
309 *E. coli* were isolated and tested individually for the MIC by standard broth micro-dilution
310 method. Pool of 40 isolated *E. coli* for each sample was also subjected for the growth curve
311 measurement as described previously.

312 **Data analyses and cost estimation**

313 In order to relate the AUC_{adj} value to the measured prevalence of resistance among selected
314 samples, we fitted a beta-regression model using the ‘*betareg*’ package in R (28). Both the trend
315 and the dispersion were allowed to vary over AUC_{adj} in a linear way.

316 AMU in flocks was quantified for the two periods defined by the sampling schedule: (1) between
317 restocking and mid-production, and (2) between mid- and end of production. Weekly estimates
318 of colistin use were expressed as the number of ADDs (number of Animal Daily Doses
319 administered per 1,000 chicken days) calculated for each of the two periods (5). Risk factors
320 associated with colistin resistance at mid- and end of production were investigated by logistic
321 regression. The outcome was colistin resistance (Yes/No) at sample level. The variables
322 investigated were: (1) Age of chicken flock (weeks); (2) Use of colistin within two weeks prior
323 to sampling (Yes/No); (3) Number of ADDs per 1,000 chicken-days of colistin in each period;
324 (4) Colistin resistance of day-old chicks (Yes/No); and (5) Number of ADDs per 1,000 chicken-
325 days of non- colistin antimicrobials used in each period. The variable Age of chicken flock was
326 included in all univariable models because it is the principal time variable. Since we had two
327 measurements per flock (mid and end cycle samples), we used generalized estimation equations
328 with an exchangeable correlation structure to estimate the parameters using the ‘*geepack*’ R
329 package (29, 30).

330 The change in AUC_{adj} over age of chicken was modeled using a random effects linear regression.
331 In order to allow for a nonlinear trend, we used a natural spline for the fixed effect term (knots at
332 0, 8, 12 and 20 weeks). We allowed for a random intercept and linear trend by age.
333 The overall costs (per sample) of the method described above were calculated based on expenses
334 on medium, reagents and consumables (excluding staff time, which was estimated separately).
335 The estimated costs were compared with those incurred in testing one sample by broth
336 microdilution and Etest in Vietnam as of January 2020. Our calculations were based on the
337 investigation of 40 *E. coli* isolates per sample using the growth-based method, compared with 10
338 isolates each by broth microdilution and by Etest.

339 **SUPPLEMENTAL MATERIAL**

340 Table S1 Estimated percentage of resistant *E. coli* from 108 samples

341 Table S2 Estimated costs (in US dollar) of testing 1 sample to determine colistin phenotypic
342 resistance of *E. coli*

343 FIG S1 Usage of colistin among study flocks by week.

344 FIG S2 Changes in AUC_{adj} by age (weeks) of chicken at the time of sampling.

345 **ACKNOWLEDGEMENT**

346 We would like to thank staff at the Sub-Department of Animal Health and Production (Dong
347 Thap) for their supports in sample and data collection. This work was funded by the Wellcome
348 Trust through an Intermediate Clinical Fellowship awarded to Juan Carrique-Mas (Grant No.
349 110085/Z/15/Z).

350 We declare that we have no competing interests.

351 N.T.N and J.C-M conceived the idea; J.C, G.T and S.B advised on the study design; N.V.C and
352 B.T.K coordinated field sampling and data collection; N.T.N, N.T.P.Y. and N.V.K.T performed
353 laboratory experiments. N.T.N, R.B.G and J.C-M conducted data analyses and produced first
354 draft. All authors commented on subsequent versions.

355 REFERENCES

- 356 1. WHO. Critically important antimicrobials for human medicine-5th rev. Geneva;2017.
357 Licence:CCBY-NC-SA 3.0 IGO. 2017.
- 358 2. Wang R, Van Dorp L, Shaw LP, Bradley P, Wang Q, Wang X, Jin L, Zhang Q, Liu Y,
359 Rieux A, Dorai-Schneiders T, Weinert LA, Iqbal Z, Didelot X, Wang H, Balloux F. 2018.
360 The global distribution and spread of the mobilized colistin resistance gene *mcr-1*. *Nat*
361 *Commun* 9:1–9.
- 362 3. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang
363 X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016.
364 Emergence of plasmid-mediated colistin resistance mechanism *MCR-1* in animals and
365 human beings in China: a microbiological and molecular biological study. *Lancet Infect*
366 *Dis* 16:161–168.
- 367 4. Cuong N V, Padungtod P, Thwaites G, Carrique-Mas JJ. 2018. Antimicrobial usage in
368 animal production: A review of the literature with a focus on low-and middle-income
369 countries. *Antibiotics* 7.
- 370 5. Cuong N V, Phu DH, Van NTB, Truong BD, Kiet BT, Hien BV, Thu HTV, Choisy M,
371 Padungtod P, Thwaites G, Carrique-Mas J. 2019. High-resolution monitoring of
372 antimicrobial consumption in Vietnamese small-scale chicken farms highlights
373 discrepancies between study metrics. *Front Vet Sci* 6:174.

- 374 6. Carrique-Mas J, Trung N V, Hoa NT, Mai HH, Thanh TT, Campbell J, Wagenaar J,
375 Hardon A, Hieu TQ, Schultsz C. 2015. Antimicrobial usage in chicken production in the
376 Mekong delta of Vietnam. *Zoonoses Public Heal* 62:70–78.
- 377 7. Trung NV, Matamoros S, Carrique-Mas JJ, Nghia NH, Nhung NT, Chieu TTB, Mai HH,
378 Rooijen W van, Campbell J, Wagenaar JA, Hardon A, Thi N, Mai N, Hieu TQ, Thwaites
379 G, Jong MD De, Schultsz C, Hoa NT. 2017. Zoonotic transmission of *mcr-1* colistin
380 resistance gene from small-scale poultry farms, Vietnam. *Emerg Infect Dis* 23:529–532.
- 381 8. Nguyen NT, Nguyen HM, Nguyen C V, Nguyen T V, Nguyen MT, Thai HQ, Ho MH,
382 Thwaites G, Ngo HT, Baker S, Carrique-Mas J. 2016. Use of colistin and other critical
383 antimicrobials on pig and chicken farms in Southern Vietnam and its association with
384 resistance in commensal *Escherichia coli* bacteria. *Appl Env Microbiol* 82:3727–3735.
- 385 9. Tadesse DA, Zhao S, Tong E, Ayers S, Singh A, Bartholomew MJ, Mcdermott PF. 2012.
386 Antimicrobial drug resistance in *Escherichia coli* from humans and food animals, United
387 States, 1950–2002. *Emerg Infect Dis* 18:741–749.
- 388 10. EFSA. 2019. The European union summary report on antimicrobial resistance in zoonotic
389 and indicator bacteria from humans, animals and food in 2017. *EFSA J* 2019 17:5598.
- 390 11. Nguyen VT, Carrique-Mas JJ, Ngo TH, Ho HM, Ha TT, Campbell JJ, Nguyen TN, Hoang
391 NN, Pham VM, Wagenaar JA, Hardon A, Thai QH, Schultsz C. 2015. Prevalence and risk
392 factors for carriage of antimicrobial-resistant *Escherichia coli* on household and small-
393 scale chicken farms in the Mekong Delta of Vietnam. *J Antimicrob Chemother* 70:2144–
394 2152.
- 395 12. EUCAST. 2016. Recommendations for MIC determination of colistin (polymyxin E) as
396 recommended by the joint CLSI-EUCAST polymyxin breakpoints working group.

- 397 [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Rec](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf)
398 [ommendations_for_MIC_determination_of_colistin_March_2016.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf).
- 399 13. WHO. 2018. The detection and reporting of colistin resistance. WHO/WSI/AMR/2018.4.
400 Licence: CC BY-NC-SA 3.0 IGO.
- 401 14. Nhung NT, Cuong N V, Campbell J, Hoa NT, Bryant JE, Truc VN, Kiet BT, Jombart T,
402 Trung N V, Hien VB, Thwaites G, Baker S, Carrique-Mas J. 2015. High levels of
403 antimicrobial resistance among *Escherichia coli* isolates from livestock farms and
404 synanthropic rats and shrews in the Mekong Delta of Vietnam. *Appl Env Microbiol*
405 81:812–820.
- 406 15. Nhung NT, Cuong N V, Thwaites G, Carrique-Mas J. 2016. Antimicrobial usage and
407 antimicrobial resistance in animal production in Southeast Asia: a review. *Antibiot* 5.
- 408 16. Apostolakos I, Piccirillo A. 2018. A review on the current situation and challenges of
409 colistin resistance in poultry production. *Avian Pathol* 47:546–558.
- 410 17. Van Cuong N, Nhung NT, Nghia NH, Mai Hoa NT, Trung NV, Thwaites G, Carrique-
411 Mas J. 2016. Antimicrobial consumption in medicated feeds in Vietnamese pig and
412 poultry production. *Ecohealth* 13:490–498.
- 413 18. Thamlikitkul V, Rattanaumpawan P, Boonyasiri A, Pumsuwan V, Judaeng T, Tiengrim S,
414 Paveenkittiporn W, Rojanasthien S, Jaroenpoj S, Issaracharnvanich S. 2015. Thailand
415 antimicrobial resistance containment and prevention program. *J Glob Antimicrob Resist*
416 3:290–294.
- 417 19. Walsh TR, Wu Y. 2016. China bans colistin as a feed additive for animals. *Lancet Infect*
418 *Dis* 16:1102–1103.
- 419 20. Indian Ministry of Health and Family Welfare. Prohibition of colistin for food producing

- 420 animals, poultry, aqua farming and animal feed supplements under Sec.26A. 2019.
- 421 <https://cdsco.gov.in/opencms/opencms/system/modules/CDSOWEB/elements/download>
- 422 [_file_division.jsp?num_id=NDY4MA==](#).
- 423 21. Osei Sekyere J. 2019. *Mcr* colistin resistance gene: a systematic review of current
- 424 diagnostics and detection methods. *Microbiol Open* 8:1–21.
- 425 22. Gillor O, Kirkup BC, Riley MA. 2004. Colicins and microcins: The next generation
- 426 antimicrobials. *Adv Appl Microbiol* 54:129–46.
- 427 23. Le Devendec L, Mourand G, Bougeard S, Léaustic J, Jouy E, Keita A, Couet W, Rousset
- 428 N, Kempf I. 2016. Impact of colistin sulfate treatment of broilers on the presence of
- 429 resistant bacteria and resistance genes in stored or composted manure. *Vet Microbiol*
- 430 194:98–106.
- 431 24. Zając M, Sztromwasser P, Bortolaia V, Leekitcharoenphon P, Cavaco LM, Ziętek-Barszcz
- 432 A, Hendriksen RS, Wasyl D. 2019. Occurrence and characterization of *mcr-1*-positive
- 433 *Escherichia coli* isolated from food-producing animals in Poland, 2011–2016. *Front*
- 434 *Microbiol* 10.
- 435 25. Arcilla MS, van Hattem JM, Matamoros S, Melles DC, Penders J, de Jong MD, Schultsz
- 436 C. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:147–
- 437 149.
- 438 26. Choi Y, Lee JY, Lee H, Park M, Kang KJ, Lim SK, Shin D, Ko KS. 2020. Comparison of
- 439 fitness cost and virulence in chromosome- and plasmid-mediated colistin-resistant
- 440 *Escherichia coli*. *Front Microbiol* 11:1–14.
- 441 27. Carrique-Mas JJ, Rushton J. 2017. Integrated interventions to tackle antimicrobial usage
- 442 in animal production systems: The ViParc project in Vietnam. *Front Microbiol* 8:1062.

- 443 28. Cribari-Neto F, Zeileis A. 2010. Beta regression in R. J Stat Softw.
- 444 29. R Core Team. 2019. R: A language and environment for statistical computing. Vienna,
445 Austria.
- 446 30. Halekoh U, Højsgaard S, Yan J. 2006. The R package geepack for generalized estimating
447 equations. J Stat Softw.
- 448

449 TABLE 1 Description of AMU and estimated prevalence of colistin resistance in 36 small-scale
450 chicken flocks stratified by whether farmers administered colistin or not.


	Flocks not using colistin (n=14)	Flocks using colistin (n=22)	All flocks (n=36)
Cycle duration (weeks) (median [1 st - 3 rd quartile])	19 [17-20]	20 [17-21]	19 [17-20]
No. chickens (median [1 st - 3 rd quartile])	249 [194-482]	208 [128-398]	231 [189-401]
No. ADDs of colistin (per 1,000 chicken-days) (mean ± SD)			
First period	0	281.7 ±321.2	172.1 ± 285.1
Second period	0	17.4 ±18.1	10.6 ± 16.4
Whole production cycle	0	149.5 ±261.6	91.4 ± 216.4
No. ADDs of non-colistin antimicrobials (per 1,000 chicken-days) (mean ± SD)			
First period	345.5 ± 471.5	629.3 ±359.8	518.9 ± 424.2
Second period	29.0 ± 48.6	72.5 ± 98.5	55.6 ± 84.7
Whole production cycle	187.2 ±366.2	350.9 ± 383.8	287.3 ± 382.9
No. flocks using colistin two weeks prior to			
Mid-sampling	0	11	11
End of sampling	0	1	1
AUC _{adj} (median, [1 st - 3 rd quartile])			
Day-olds	0.07 [0.04-0.42]	0.06 [0.04-0.52]	0.07 [0.04-0.65]
Mid-production	0.06 [0.03-0.43]	0.54 [0.07-0.65]	0.20 [0.05-0.63]
End of production	0.07 [0.06-0.55]	0.07[0.06-0.55]	0.07 [0.05-0.56]
Prevalence of resistance (%) at sample level (95% CI)			
Day-olds	42.8 (18.8-70.3)	31.8 (14.7-54.9)	36.1 (21.3-53.8)
Mid-production	28.6 (9.5-58.0)	63.6 (40.8-82.0)	50.0 (34.5- 65.5)
End of production	28.6 (9.5-58.0)	31.8 (14.7-54.9)	30.5 (16.9- 48.3)
Estimated prevalence of resistance (%) at colony level (mean ± SD)			
Day-olds	28.8 ±36.0	15.7 ±24.7	20.8 ±29.8
Mid-production	17.3 ±28.7	27.0 ±26.4	23.3 ±27.4
End of production	16.2 ±24.8	12.8 ±18.1	14.1 ±20.7

451 AUC= area under the growth curve; CI= Confidence interval; SD= standard deviation

452 TABLE 2 Logistic regression models investigating risk factors associated with colistin resistance
 453 in chicken flocks at sample level. Models were based on a total of 72 samples (mid and end
 454 production); 29 were positive resistance to colistin.


Variable	Univariable ^a			Multivariable		
	OR	95% CI	p-value	OR	95% CI	p-value
Age of chicken flock (weeks)	0.93	0.84-1.02	0.156	1.04	0.91-1.18	0.605
Use of colistin within last two weeks (Yes/No)	5.30	1.17-24.08	0.030	3.67	0.68-19.70	0.128
No. ADDs per 1,000 chicken-day of colistin ^b	1.66	1.00-2.76	0.049	1.06	0.55-2.06	0.845
Colistin resistance of day-old chicks (Yes/No)	1.45	0.53-3.97	0.461	1.61	0.54-4.84	0.395
No. ADDs per 1,000 chicken-day of non- colistin antimicrobials ^b	2.10	1.18- 3.73	0.012	1.84	0.88-3.85	0.102

455 ^aThe variable ‘Age of chicken flock’ was included in all univariable models to calculate estimates for all subsequent
 456 variables. ^blogarith transformed after adding 1, ADD= animal daily dose; OR= Odds ratio; CI= Confidence interval.



457

458 FIG 1 AUC_{adj} of standard suspensions. Positive growth values are represented by increasing strength of color. R= Resistant, S=
 459 Susceptible. Average of AUC_{adj} of resistant strain 1, 2, 3 and 4 was 0.40, 0.30, 0.41 and 0.26, respectively. Average AUC_{adj} of
 460 susceptible strain 1, 2, 3 and 4 was 0.41, 0.19, 0.31 and 0.54 respectively.



462 FIG 2 Relationship between AUC_{adj} and prevalence of colistin resistance at colony level. The
463 figure shows the predicted mean value of resistance with pointwise 95% confidence as shaded
464 area. The dotted lines give the 5% and 95% prediction intervals. Circle symbols indicated
465 AUC_{adj} values of mixed *E. coli* in field samples. Size of dot represented the average MIC of each
466 sample. Cross symbols indicated AUC_{adj} values of mixed susceptible and resistant strains.